Market capitalization | $1.49b |
Enterprise Value | $1.44b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.22 |
P/S ratio (TTM) P/S ratio | 3.34 |
P/B ratio (TTM) P/B ratio | 3.21 |
Revenue growth (TTM) Revenue growth | 17.56% |
Revenue (TTM) Revenue | $447.57m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
9 Analysts have issued a AtriCure, Inc. forecast:
9 Analysts have issued a AtriCure, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 448 448 |
18%
18%
|
|
Gross Profit | 332 332 |
16%
16%
|
|
EBITDA | -16 -16 |
18%
18%
|
EBIT (Operating Income) EBIT | -34 -34 |
25%
25%
|
Net Profit | -39 -39 |
57%
57%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AtriCure, Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.
Head office | United States |
CEO | Michael Carrel |
Employees | 1,200 |
Founded | 1994 |
Website | www.atricure.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.